Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.

Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.

BACKGROUND: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with H...

Full description

Bibliographic Details
Main Authors:	Ming-Lun Yeh, Chao-Hung Hung, Jee-Fu Huang, Chun-Jen Liu, Chuan-Mo Lee, Chia-Yen Dai, Jing-Houng Wang, Zu-Yau Lin, Sheng-Nan Lu, Tsung-Hui Hu, Ming-Lung Yu, Jia-Horng Kao, Wan-Long Chuang, Pei-Jer Chen, Ding-Shinn Chen
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3113900?pdf=render

Similar Items

Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen
by: Chueh-An Chen, et al.
Published: (2007)

Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
by: Yi-Hao Yen, et al.
Published: (2015-07-01)

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection
by: Ta-Ya Lin, et al.
Published: (2017-06-01)

Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance
by: Hyun Woong Lee, et al.
Published: (2020-04-01)

Spontaneous Hepatitis B Seroclearance upon Development of Hepatocellular Carcinoma
by: Sara Naimimohasses, et al.
Published: (2017-12-01)

Artificial neural network accurately predicts hepatitis B surface antigen seroclearance.
by: Ming-Hua Zheng, et al.
Published: (2014-01-01)

Ribavirin plus interferon alfa in the treatment of chronic hepatitis C infection
by: Wen Hwang Chen, et al.
Published: (2000)

Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients.
by: Huei-Ru Cheng, et al.
Published: (2013-01-01)

Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B.
by: Tae Hyung Kim, et al.
Published: (2018-01-01)

The Association of Liver Fibrosis with Effectiveness of Pegylated Interferon Alfa-2b Plus Ribavirin for Chronic Hepatitis C
by: Yi-chih Chen, et al.
Published: (2007)

Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
by: Guei-Ying Chen, et al.
Published: (2015-11-01)

Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
by: T Kanda, et al.
Published: (2011-03-01)

Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance
by: Hideaki Taniguchi, et al.
Published: (2020-08-01)

Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function.
by: Tai-Long Chien, et al.
Published: (2016-01-01)

Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents
by: Jaber Al Ali, et al.
Published: (2010-04-01)

Incidence and Determinants of Seroclearance of Hepatitis B e Antigen and Its Association with Risk of Liver Cirrhosis and HCC
by: Hsiu-Lien Hung, et al.
Published: (2010)

HBS Ag seroclearance and seroconversion time in patients with chronic hepatitis B infection
by: jila Masrour-Roudsari, et al.
Published: (2020-03-01)

Using Machine Learning Algorithms to Predict Hepatitis B Surface Antigen Seroclearance
by: Xiaolu Tian, et al.
Published: (2019-01-01)

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.
by: Ming-Lung Yu, et al.
Published: (2012-01-01)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01)

Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
by: Ming-Yen Hsieh, et al.
Published: (2012-02-01)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
by: Ming-Te Kuo, et al.
Published: (2014-01-01)

A Comparison of Interferon-Alpha-2b Induction Therapy with Interferon-Alpha-2b Plus Ribavirin Combination Therapy for the Treatment of Chronic Hepatitis C
by: Bilgehan AYGEN, et al.
Published: (2004-09-01)

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
by: Ta-Wei Liu, et al.
Published: (2018-01-01)

Clinical characteristics and virological responses to pegylated interferon plus ribavirin combination therapy in the hepatitis B and C virus coinfected patients
by: J. You, et al.
Published: (2014-04-01)

Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection
by: Ching-Chung Lin, et al.
Published: (2014-07-01)

Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy
by: Zhu Xiaolin, et al.
Published: (2011-02-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

Autoantibodies profile in patients with chronic hepatitis C and the influence of Interferon-alfa plus Ribavirin
by: Janaina LeitÃo Vilar
Published: (2006)

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
by: Chen-Hua Liu, et al.
Published: (2020-12-01)

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
by: Jeong Won Jang, et al.
Published: (2021-01-01)

Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
by: Meng-Hsuan Hsieh, et al.
Published: (2018-06-01)

Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.
by: Tetsuro Takayama, et al.
Published: (2011-01-01)

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C
by: Chao-Hung Hung, et al.
Published: (2016-04-01)

Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C Recombinant Interferon alfa-2b plus Ribavirin in treatment of chronic hepatitis C
by: Yoan Antonio Sánchez Rodríguez, et al.
Published: (2010-06-01)

High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C
by: David N Moskovitz, et al.
Published: (2003-01-01)

Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice
by: Luisa Cavalletto, et al.
Published: (2008-01-01)

Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin.
by: José Manuel Cuevas, et al.
Published: (2008-08-01)

The effect of zinc status improvement on the alpha- interferon plus ribavirin efficiency in hepatitis C patients
by: 邱雅鈴
Published: (2001)